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SUMMARY
The EGFR T790M mutation has been identified in tumors from lung cancer patients that eventually
develop resistance to erlotinib. In this study, we generated a mouse model with doxycycline-induc-
ible expression of a mutant EGFR containing both L858R, an erlotinib-sensitizing mutation, and the
T790M resistance mutation (EGFR TL). Expression of EGFR TL led to development of peripheral
adenocarcinomas with bronchioloalveolar features in alveoli as well as papillary adenocarcinomas
in bronchioles. Treatment with an irreversible EGFR tyrosine kinase inhibitor (TKI), HKI-272, shrunk
only peripheral tumors but not bronchial tumors. However, the combination of HKI-272 and rapamy-
cin resulted in significant regression of both types of lung tumors. This combination therapy may
potentially benefit lung cancer patients with the EGFR T790M mutation.INTRODUCTION
EGFR is a member of the ErbB receptor tyrosine kinase
family that also includes HER2/ErbB2/neu, HER3/ErbB3,and HER4/ErbB4. Point mutations and deletion mutations
in the kinase domain of EGFR have been found to corre-
late with response to the reversible TKIs gefitinib and erlo-
tinib (Pao et al., 2005). Most EGFR mutations fall into fourSIGNIFICANCE
The secondary mutation T790M in the EGFR kinase domain is associated with acquired resistance to erlotinib in
patients with non-small-cell lung cancer (NSCLC). We demonstrate that expression of an EGFR mutant with
a T790M-L858R compound mutation in the kinase domain is oncogenic in a mouse model and is essential for
tumor maintenance. Combination treatment with the dual-specificity EGFR/ErbB2 irreversible inhibitor HKI-272
and rapamycin induced dramatic tumor regression in these erlotinib-resistant mouse lung cancers, whereas rapa-
mycin or HKI-272 alone failed to produce significant responses. Our findings uncover a potential limitation of
irreversible TKI therapy against lung cancers harboring EGFR TL and offer an alternative therapeutic strategy
for NSCLC patients who eventually develop erlotinib resistance.Cancer Cell 12, 81–93, July 2007 ª2007 Elsevier Inc. 81
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HKI-272 and Rapamycin Inhibit Murine Lung Cancermajor classes: single-base substitutions in exon 18; dele-
tions in exon 19; insertion/duplications in exon 20; and
a single-base substitution, L858R, in exon 21 (Shigematsu
and Gazdar, 2006). ErbB2 is a favored heterodimerization
partner for EGFR and may be expressed at high levels in
NSCLC, in some cases as a result of gene amplification.
Both EGFR and ErbB2 transphosphorylate ErbB3, which
controls PI3K survival signaling in ErbB-driven cancers
(Engelman and Cantley, 2006).
Although large phase III trials have shown that erlotinib
prolongs survival (Shepherd et al., 2005), patients who
initially respond to this TKI almost invariably develop
drug resistance. It is estimated that approximately 50%
of acquired erlotinib resistance is due to the emergence
of a secondary mutation, T790M, in the kinase domain of
EGFR (Johnson et al., 2006; Riely et al., 2006). Structural
analyses suggest that the T790M mutation appears to ste-
rically hinder the binding of erlotinib to the EGFR kinase
domain by introduction of a bulky methionine residue,
thereby conferring resistance to the drug (Kobayashi
et al., 2005a; Pao et al., 2005). Of note, a recent study iden-
tified the EGFR T790M mutation as a germline allele in
a lung-cancer-prone family, suggesting that this mutation
alone may harbor oncogenic potential (Bell et al., 2005).
In order to overcome resistance conferred by the EGFR
T790M mutation, the use of irreversible dual-specificity
EGFR/ErbB2 inhibitors has been proposed (Kobayashi
et al., 2005b). HKI-272 belongs to this class of inhibitors
and is one of the first in clinical trials. In vitro studies
have shown that HKI-272 is an effective inhibitor of the
EGFR T790M mutation (Kwak et al., 2005). Additionally,
we have previously shown that HKI-272 has similar or
better efficacy than erlotinib in treating activating EGFR
kinase domain mutant- and EGFRvIII-driven mouse lung
adenocarcinomas (Ji et al., 2006a, 2006b). However, it
remains unknown if this class of ErbB family inhibitors
will effectively treat human lung cancers harboring the
EGFR T790M mutation.
Mounting evidence suggests that the PI3K/Akt/mTOR
pathway plays a pivotal role in tumorigenesis and tumor
maintenance (Engelman et al., 2005). Activated mTOR
signaling, defined by expression of phospho-S6 in tumor
tissue, has been associated with EGFR mutant lung can-
cers (Conde et al., 2006). mTOR integrates signals from
both growth factor and nutrient transduction pathways
(Vogt, 2001) and is critical for ribosome biogenesis and
cell growth (Hay and Sonenberg, 2004). However, rapa-
mycin analogs have shown limited efficacy in clinical trials
(Vignot et al., 2005). This may be partially due to the abro-
gation of mTOR-S6-dependent feedback inhibition of
both insulin-like growth factor receptor substrate-1 (IRS-1)
and PI3K/Akt signaling (Manning, 2004; O’Reilly et al.,
2006). Rapamycin may also inhibit mTOR-S6-mediated
negative feedback of other growth factor receptors as
well (Hay, 2005).
To evaluate the biological function of the compound
EGFR TL mutation in lung tumorigenesis and its sensitivity
to TKIs, we generated a doxycycline-inducible bitrans-
genic mouse model that expresses EGFR TL. Our data82 Cancer Cell 12, 81–93, July 2007 ª2007 Elsevier Inc.reveal that lung-specific expression of EGFR TL leads to
development of lung adenocarcinomas that are depen-
dent on EGFR signaling for their continued survival.
EGFR TL-driven tumors are resistant to erlotinib but
show dramatic response to HKI-272 and rapamycin com-
bination therapy, suggesting that suppression of both
EGFR activation and downstream PI3K-mTOR signaling
is important for the efficacy of this therapeutic strategy.
RESULTS
Generation of the Tet-op-EGFR TL/CCSP-rtTA
Mouse Cohort
To generate mice with inducible expression of the human
EGFR TL compound mutant, we constructed a 4.7 kb DNA
segment consisting of seven direct repeats of the tetra-
cycline (tet)-operator sequence, followed by EGFR TL
cDNA and b-globin polyA (Figure 1A and Experimental
Procedures). The construct was injected into FVB/N blas-
tocysts, and progeny were screened using a PCR strategy
(data not shown). Fifteen Tet-op-EGFR TL founders were
identified and then crossed to CCSP-rtTA mice, an allele
that has been shown to specifically target the expression
of the reverse tetracycline transactivator protein (rtTA) in
type II alveolar epithelial cells, to generate inducible bi-
transgenic mouse cohorts harboring both the activator
and the responder transgenes (Fisher et al., 2001). Four
tightly regulated EGFR TL founders (#17, #19, #24, and
#29) were identified by RT-PCR (Figure 1B). The gene
copy number from individual founders was determined
by quantitative real-time PCR (Figure 1C).
Tightly Regulated Expression of EGFR TL mRNA
in Lung Tissue
The inducibility of transgene expression in the lung com-
partment was evaluated at the RNA level by RT-PCR.
The lungs of the bitransgenic mouse Tet-op-EGFR
TL/CCSP-rtTA cohort for each potential founder were col-
lected before and after 8 weeks of doxycycline adminis-
tration and after 3 days of doxycycline withdrawal follow-
ing doxycycline administration over an 8 week period. The
EGFR mutant transcript was undetectable from either
nontransgenic mice or the bitransgenic mice without
doxycycline treatment, while it became readily detectable
after 8 weeks of doxycycline administration; transcription
of mutant EGFR was completely abolished by 3 days of
doxycycline withdrawal in all of the lines (Figure 1B and
data not shown). To further confirm that mutant EGFR
transcripts are inducible and tightly regulated by doxycy-
cline, both RT-PCR and quantitative real-time PCR were
performed on lung samples collected at serial time points
of doxycycline administration and withdrawal from
founder #19. Mutant EGFR expression was observed after
1 week of doxycycline administration and was kept at
a comparable level throughout the 8 week period of ad-
ministration (Figure 1D). Doxycycline withdrawal was
sufficient to block the expression of mutant EGFR, and
no expression of the transgene was observed after 12
weeks of doxycycline withdrawal (Figure 1D).
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HKI-272 and Rapamycin Inhibit Murine Lung CancerFigure 1. Generation and Characterization of the Bitransgenic Mice with Inducible Expression of EGFR TL in Lung Compartments
(A) Scheme of the EGFR TL construct for the conditional transgenic mice.
(B) RT-PCR analysis of regulatable expression of EGFR TL in lungs of bitransgenic mice derived from four founders. , on regular food; +, on
doxycycline food for 8 weeks; +/, on doxycycline food for 8 weeks followed by 3 days of regular food.
(C) EGFR TL copy number for each founder line. Copy numbers were determined by real-time PCR using tail DNA. Means (columns) and standard
deviations (SD; bars) shown were from triplicate experiments.
(D) Time course analysis of EGFR TL expression in founder #19. Expression level was evaluated by regular RT-PCR (left panel) and real-time PCR
(right panel) at different time points after indicated doxycycline treatment. Triplicate experiments were performed for each sample.Overexpression of the EGFR TL Mutant Drives
the Development of Two Distinct Types
of Lung Adenocarcinomas
To determine if overexpression of the EGFR mutant
would drive lung tumorigenesis, bitransgenic Tet-op-
EGFR TL/CCSP-rtTA mice on continuous doxycycline
administration underwent serial magnetic resonance
imaging (MRI) and were sacrificed at various time points
for histological examination of the lungs. Tumors could
be observed by MRI after 5–6 weeks of doxycycline
administration, and tumor volume, as defined by MRI,
increased following prolonged doxycycline treatment
(Figure 2A, top row). In contrast to untreated mice, lung
histology demonstrated the development of early lesions
in alveoli after 2–3 weeks of doxycycline treatment. After
4–5 weeks, typical bronchioloalveolar carcinoma (BAC)
appeared. Invasive peripheral adenocarcinomas with
bronchioloalveolar features appeared after 7–9 weeks
and become the dominant histological pattern after 12
weeks of doxycycline treatment (Figure 2A, middle row).
The lung peripheral adenocarcinomas observed are histo-
logically similar to those that develop in the EGFR L858R
mouse model described previously (Ji et al., 2006a; Politi
et al., 2006) and are also similar to a subset of erlotinib-
sensitive NSCLC occurring in patients.
In addition to peripheral adenocarcinomas, Tet-op-
EGFR TL/CCSP-rtTA mice also developed bronchial
papillary adenocarcinomas. Early papillary neoplasias inthe bronchioles were observed after 2–3 weeks of contin-
uous doxycycline administration. These lesions subse-
quently progressed into adenocarcinomas after an addi-
tional 6–8 weeks (Figure 2A, bottom row). Bronchial
papillary tumors were found in all of the four identified
founders of Tet-op-EGFR TL/CCSP-rtTA mice but were
absent in all three EGFR L858R founders (Figure 2B).
All of the four Tet-op-EGFR TL/CCSP-rtTA founders
showed similar morphologic features and a similar latency
in tumorigenesis (representative photos shown in Fig-
ure 2A were from founder #19). In addition, metastatic
foci of adenocarcinomas were occasionally observed in
lymph nodes of the mice harboring EGFR TL-driven
lung tumors but not in mice harboring EGFR L858R-driven
tumors.
Immunohistochemical (IHC) staining for both peripheral
and bronchial tumors with prosurfactant protein C (SPC),
a unique biomarker for type II pneumocytes in the alveoli,
and Clara cell secretory protein (CCSP), a specific marker
for Clara cells in bronchiolar epithelium, demonstrated dif-
ferent patterns of differentiation. The majority of peripheral
tumors showed intensive SPC staining, implying a type II
pneumocyte origin, as expected. In contrast, the bronchial
tumors were completely negative for SPC. Interestingly,
only a small subset of bronchial tumor cells were positive
for CCSP (Figure 3D). It is possible that these tumors are of
Clara cell origin, followed by compromised differentiation
leading to loss of the CCSP expression marker.Cancer Cell 12, 81–93, July 2007 ª2007 Elsevier Inc. 83
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HKI-272 and Rapamycin Inhibit Murine Lung CancerFigure 2. Expression of EGFR TL In-
duces Adenocarcinomas with BAC
Features in Alveoli and Papillary Adeno-
carcinomas in the Bronchioles
(A) Time course analysis of lung tumorigenesis
in alveoli and bronchioles after doxycycline
administration using both MRI and histology
inspection. MRI photographs show increased
tumor volume with time of doxycycline admin-
istration (top row; H, heart area). Hematoxylin
and eosin (H&E)-stained lung sections from
the same mice shown in the top row reveal
both adenocarcinomas in alveoli and also pap-
illary adenocarcinomas in bronchioles (middle
and bottom rows, respectively; arrows, early
neoplastic lesions). Photos show representa-
tive tumor lesions in the lungs representing
average tumor burden among doxycycline-
treated mice but not the most severe lesions
at particular time point, as emphasized in the
text.
(B) Histological comparison between the mu-
rine lung tumors with EGFR L858R mutation
and EGFR TL mutation (from all four founders).
Note that papillary bronchial tumors were not
seen in EGFR L858R mice but observed in all
of EGFR TL founders. The photographs from
founders #19 and #24 also show obstructive
pneumonia in addition to bronchial tumors
(bottom row).Expression of the EGFR TL Mutant Is Essential
for Tumor Maintenance of Both Peripheral
and Bronchial Adenocarcinomas
Both peripheral and bronchial lung adenocarcinomas
from EGFR TL/CCSP-rtTA mice stained positively for total
and phospho-EGFR antibodies (Figure 3A, Figure S1 in
the Supplemental Data available with this article online,
and data not shown), indicating that the expressed
EGFR mutant is functionally active. After 3 days of doxycy-
cline withdrawal, no staining with either antibody was ob-
served (Figure 3A and data not shown), implying that both
types of tumors are driven by and dependent on EGFR TL
for their survival. We also observed an increase in terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick
end labeling (TUNEL) staining (72 hr) and cleaved caspase
3 staining (48 hr) after doxycycline withdrawal, indicating
that apoptosis had been triggered (Figure 3A, bottom
row, and Figure S2, respectively). Furthermore, PCNA
staining at 48 hr of doxycycline withdrawal showed de-
creased proliferation of cancer cells (Figure S2).
Consistent with the increased apoptosis and decreased
proliferation suggested by TUNEL and PCNA staining,
MRI results demonstrated that EGFR TL-driven lung
tumors completely regressed by 10 days after doxycycline
withdrawal (Figure 3B). Microscopic analysis of the lungs
from the same mouse that was examined by MRI showed
grossly normal lung histology (Figure 3B). No tumor le-
sions were found in either alveoli or airways after 12 weeks84 Cancer Cell 12, 81–93, July 2007 ª2007 Elsevier Inc.of doxycycline withdrawal in other tumor-bearing mice
(data not shown).
To better quantify mutant EGFR expression in tumors at
the protein level, we performed western blotting using
whole-lung lysates from bitransgenic mice after different
durations of doxycycline administration. Although individ-
ual differences existed, EGFR phosphorylation was tightly
regulated by doxycycline and was synchronized with the
presence of tumors (Figure 3C), confirming the essential
role of mutant EGFR signaling in tumor maintenance as
observed in IHC staining and MRI. Therefore, EGFR re-
mains an attractive therapeutic target for tumors induced
in this mouse model.
The Two Types of EGFR TL Mutant-Driven Lung
Adenocarcinomas Are Resistant to Erlotinib
but Show Differing Sensitivities to HKI-272
To investigate the sensitivity of the EGFR TL-driven lung
tumors to different EGFR-targeted therapies, we serially
imaged the bitransgenic mice exposed to continuous
doxycycline before and after treatment with erlotinib or
HKI-272. After 8–10 weeks of doxycycline treatment,
bitransgenic Tet-op-EGFR TL/CCSP-rtTA mice were
screened by MRI to document the baseline tumor burden.
Tumor-bearing mice were then treated orally with erlotinib
(four mice), HKI-272 (eight mice), or placebo (three mice)
while being kept on continuous doxycycline administra-
tion. Erlotinib and HKI-272 were given orally for 2 and 3
Cancer Cell
HKI-272 and Rapamycin Inhibit Murine Lung CancerFigure 3. Both Peripheral and Bronchial Tumors Are Dependent on EGFR TL Expression for Their Survival but Originate from
Different Respiratory Epithelial Cell Types
(A) Peripheral tumors driven by EGFR T790M-L858R contained abundant total EGFR protein that was functionally active. Peripheral tumors from
EGFR TL mice were intensively stained by antibodies against total and phospho-EGFR (Y1068) (top left and middle left panels, respectively).
Doxycycline withdrawal completely eliminated the staining by both antibodies in tumors (top right and middle right panels) and also induced apoptosis
of tumor cells as indicated by TUNEL staining (bottom row; on doxy, doxycycline administration for 9 weeks; off doxy, doxycycline withdrawal for
3 days after 10 weeks of doxycycline administration; arrow, apoptotic nuclei). Inset in each 8003 high-magnification immunohistochemistry photo-
graph shows a low-magnification (803) photo from the same tumor. Bar diagrams expressed as mean ± SD illustrate the apoptotic indices in lung
tumors before and after 3 days of doxycycline withdrawal, determined from at least 200 high-power fields (HPF). Statistical analyses were performed
using Student’s t test.
(B) Doxycycline withdrawal for 10 days induced complete tumor regression in EGFR TL mice. Photographs show MRI scans from a mouse that
received 8 weeks of doxycycline diet, before and after doxycycline withdrawal for 10 days (left and middle panels, respectively; H, heart area).
H&E staining of the same mouse showed no tumor in either alveoli or bronchioles (right panel).
(C) EGFR and phospho-EGFR expression is synchronized with doxycycline administration. Whole-lung lysates from mice at the indicated time points
after doxycycline administration were subjected to western blotting with anti-total EGFR and anti-phospho-EGFR (Y1068) antibodies (top and middle
panels, respectively). The analysis for b-actin demonstrates equal loading in each lane (bottom panel).
(D) EGFR TL-induced peripheral tumors originated from typed II pneumocytes, while bronchial tumors originated from Clara cells. Sections were
stained with antibodies against type II pneumocyte-specific SPC and Clara-cell-specific CCSP (top and bottom rows, respectively).weeks, respectively, at a daily dose (50 mg/kg) that has
been proven to be effective in treating mouse lung adeno-
carcinomas driven by EGFR L858R single mutation (Ji
et al., 2006a). None of the EGFR TL/CCSP-rtTA mice re-
ceiving erlotinib showed significant tumor reduction by
MRI. However, in the 8 mice treated with HKI-272, there
was a mixed response: some tumor lesions partially re-
gressed, while others grew. Overall, the response favored
regression (total regression rate 19.7% ± 3.2% for all eight
mice; Figure 4A, left two columns, and Figure 4B). Increas-
ing doses of HKI-272 were then administered to tumor-
bearing mice after 8 weeks of doxycycline administration
in an experiment in which ten mice were randomized to re-
ceive 100 mg/kg or 150 mg/kg daily for 3 weeks. Although
HKI-272 was well tolerated at all dosages, the higher
doses did not increase the tumor response rate (data
not shown).Histologic analysis of the lungs from mice treated with
HKI-272 alone revealed that there was a decreased
number of peripheral adenocarcinomas, and significant
treatment effect in this lung compartment as demon-
strated by decreased cellularity, increased fibrosis, and
the presence of necrosis within the residual tumor masses
(Figure 4A, bottom row, and data not shown). No signifi-
cant treatment effect was observed in erlotinib-treated
mice or placebo-treated control mice (Figure 4A, middle
and top row). In contrast to peripheral tumors, bronchial
tumors driven by EGFR TL did not respond to either erlo-
tinib or HKI-272 treatment (Figure 4A, far right column).
Focal pneumonia with an increased number of intra-alve-
olar macrophages filling the alveolar spaces was often
observed in all the mice, potentially due to airway obstruc-
tion by bronchial tumors (Figure 2B, bottom row, second
panel from left and far right panel).Cancer Cell 12, 81–93, July 2007 ª2007 Elsevier Inc. 85
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HKI-272 and Rapamycin Inhibit Murine Lung CancerFigure 4. HKI-272, but Not Erlotinib, Is Effective against EGFR TL-Driven Peripheral Tumors
(A) HKI-272 generated a mixed radiographic response in EGFR TL mice and induced histological treatment effects in peripheral tumors but not bron-
chial tumors. After approximately 8 to 10 weeks of doxycycline administration, tumor-bearing mice were identified by MRI and divided into different
treatment groups (placebo, top row; erlotinib, middle row; HKI-272, bottom row). While doxycycline was continued, all drugs were administered orally
at a dose of 50 mg/kg/day for 2 or 3 weeks; the length of drug treatment for individual mice depended on their overall condition. Mice were sacrificed
at the indicated times after reimaging. MR images taken before and after drug treatment are shown in the two left columns. Note the increased tumor
burden after erlotinib treatment and the mixed response after HKI-272 treatment (H, heart area). Representative H&E staining for both peripheral and
bronchial tumors from the lungs of the corresponding mice are shown in the two right columns.
(B) Data (expressed as mean ± SD) illustrate the degree of tumor regression evaluated by MRI. Statistical analysis was performed using Student’s
two-tailed t test.Bronchial Tumors Driven by EGFR TL Are Sensitive
to Combination Therapy with HKI-272
and Rapamycin
Since EGFR TL-driven bronchial tumors did not demon-
strate a histologic treatment effect after treatment with
HKI-272 alone, we tested whether combination therapy
with rapamycin could produce response. Rapamycin is
a specific inhibitor of mTOR, an important downstream
component of the EGFR/PI3K/Akt signaling pathway.
Five tumor-bearing mice were treated daily with HKI-272
(50 mg/kg, oral gavage) and rapamycin (2 mg/kg, i.p. injec-
tion) combination therapy for 3 weeks. Control mice were
treated with erlotinib and rapamycin combination therapy
or rapamycin alone (four mice in each group) with a similar
dosing schedule. A significant reduction in tumor volume
(72% ± 4.5%) was observed in the HKI-272 plus rapamycin
treatment group by MRI after a 3 week period, but no sig-
nificant tumor regression was found in either erlotinib plus
rapamycin or rapamycin alone groups (Figure 5A, left two
columns, and Figure 5B). Pathological examination of
mice from the respective treatment groups confirmed the
MRI findings. Residual tumors from mice in the HKI-272
and rapamycin combination treatment group demon-86 Cancer Cell 12, 81–93, July 2007 ª2007 Elsevier Inc.strated significant treatment effects in both peripheral
and bronchial tumors, with fewer tumors, decreased cellu-
larity, and increased fibrosis and necrosis. Tumors from
control treatment groups remained unaffected (Figure 5A,
right two columns, and data not shown).
HKI-272 and Rapamycin Synergistically Suppress
the PI3K-mTOR Axis Driven by EGFR TL Both
In Vitro and In Vivo
H1975 cells express EGFR harboring the TL compound
mutation and are resistant to erlotinib. Although HKI-272
was reported to suppress the growth of these cells
(Kwak et al., 2005; Shimamura et al., 2006), the IC50 was
approximately 47 times higher than that for the H3255
cell line expressing an EGFR L858R mutation (222.45
nM versus 4.78 nM; Figure 6A). The hypersensitivity of
H3255 cells to HKI-272 is consistent with previous results
evaluating its efficacy in murine model of lung cancer pro-
moted by EGFR L858R. Therefore, these in vitro results
suggest that the presence of the T790M resistance muta-
tion greatly hinders the efficacy of HKI-272.
The significant response of EGFR TL mice to HKI-272
and rapamycin combination treatment led us to evaluate
Cancer Cell
HKI-272 and Rapamycin Inhibit Murine Lung CancerFigure 5. Combination Therapy of HKI-272 and Rapamycin Is Effective for Both Peripheral and Bronchial Tumors, While the
Combination of Erlotinib and Rapamycin Has No Effects
(A) HKI-272 combined with rapamycin caused dramatic tumor regression by MRI and induced significant histological treatment effects in both
bronchial and peripheral tumors. Treatment groups and panel designations are similar to those of Figure 4A, except that all mice also received a daily
i.p. injection of 2 mg/kg rapamycin (arrows indicate residual tumors; H, heart area).
(B) Data (expressed as mean ± SD) illustrate the degree of tumor regression evaluated by MRI. Statistical analysis was performed using Student’s
two-tailed t test.the potential synergism between these two drugs. As
shown in Figure 6B, we treated a panel of NSCLC cell lines
with different EGFR mutational status [H1975 (TL), H3255
(L858R), H820 (E746_T751del-T790M), and HCC827
(E746_A750 del)] with varying concentrations of HKI-272
or rapamycin alone or in combination at a 1:50 ratio.
None of the NSCLC cell lines tested were sensitive to
treatment with rapamycin alone. H3255 cells and HCC827
cells, which harbor L858R and deletion EGFR kinase do-
main mutations, respectively, were exquisitely sensitive
to HKI-272 alone, and the sensitivity of these cells was
not significantly improved by addition of rapamycin. In
contrast, for NSCLC cell lines harboring T790M secondary
mutations, combination treatment was synergistic, indi-
cated by a marked reduction in cell survival. For example,
in H1975 cells, a 2.5-fold decrease in the IC50 value of HKI-
272 (244 nM versus 92 nM) was observed in the presence
of rapamycin (combination index [CI] = 0.762). Strikingly,
these drugs showed even stronger synergy in H820 cells,
as the IC50 of HKI-272 was reduced from more than 10 mM
to 101 nM in the presence of rapamycin (CI = 0.664).
To elucidate the mechanisms of HKI-272-rapamycin
synergy in cells harboring an EGFR T790M secondary mu-
tation, the intracellular signaling responses of H1975 cells
and H3255 cells treated with HKI-272 or rapamycin aloneor in combination were compared (Figure 6C). In HKI-272-
sensitive H3255 cells, HKI-272 alone was sufficient to
completely dephosphorylate ErbB family kinases includ-
ing EGFR (Tyr1068), ErbB2 (Tyr1221/1222), and ErbB3
(Tyr1289). The receptor tyrosine kinase (RTK) inactivation
resulted in reduced phosphorylation of Akt (Ser473), with
downstream inhibition of mTOR, as evidenced by reduced
phosphorylation of p70S6K (Thr389) and S6 (Ser240/244).
Reduced phosphorylation of Akt, p70S6K, and S6K
persisted for 24 hr and was evident on long exposure of
the respective blots. As expected, rapamycin reduced
phosphorylation of p70S6K (Thr389) and S6 (Ser240/244)
downstream of mTOR, accompanied by increased phos-
phorylation of Akt, consistent with previous reports sug-
gesting that rapamycin treatment suppresses a negative
feedback loop, resulting in activation of PI3K (Easton
et al., 2006; O’Reilly et al., 2006). The treatment of
H3255 cells with HKI-272 and rapamycin in combination
caused a marked reduction in phosphorylation of Akt,
p70S6K, and S6 that was similar to that observed with
HKI-272 alone (Figure 6C and Table S1).
In contrast to H3255 cells, H1975 cells treated with
HKI-272 resulted in reduced phosphorylation of EGFR
(Tyr1068), ErbB2 (Tyr1221/1222), and ErbB3 (Tyr1289), but re-
sidual phosphorylation of EGFR was detectable, as shownCancer Cell 12, 81–93, July 2007 ª2007 Elsevier Inc. 87
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HKI-272 and Rapamycin Inhibit Murine Lung CancerFigure 6. HKI-272 and Rapamycin Synergistically Suppress the PI3K-mTOR-S6k-S6 Axis, which Is Critical for Survival and
Proliferation of NSCLC Cells
(A) The IC50 of HKI-272 was far lower in H3255 (EGFR L858R) cells than that of H1975 (EGFR TL) cells. H3255 cells and H1975 cells were treated with
HKI-272 at the indicated concentrations in cell proliferation assays as described in the Experimental Procedures. The survival of each sample was
normalized compared to that of control DMSO-treated cells. The data points shown represent the average of normalized values ± standard error from
two independent experiments.
(B) HKI-272 and rapamycin were synergistic in NSCLC cells harboring T790M EGFR secondary mutations. H1975, H3255, H820, and HCC827 cells
were treated with the indicated concentrations of HKI-272 alone, rapamycin alone, or the two drugs concomitantly in cell proliferation assays. The
survival of each sample was normalized to that of control DMSO-treated cells. The data points shown represent the average of normalized
values ± standard error from three independent experiments. Combination indices (CI) were calculated as described in the Experimental Procedures,
demonstrating synergy in H1975 and H820 cells.
(C) HKI-272 incompletely suppresses the EGFR-Akt-mTOR-S6 axis in H1975 cells. Exponentially growing H1975 or H3255 cells were treated with
vehicle (DMSO), HKI-272 (800 nM), rapamycin (16 nM), or combined HKI-272 (800 nM) and rapamycin (16 nM). At the indicated time points,
whole-cell lysates were harvested and subjected to SDS-PAGE, followed by western blotting with the indicated antibodies. Phosphorylation of
Akt, Erk, S6K, and S6 was effectively reduced by HKI-272 alone in H3255 cells. However, a similar degree of dephosphorylation of these proteins
required the combination of HKI-272 and rapamycin in H1975 cells.88 Cancer Cell 12, 81–93, July 2007 ª2007 Elsevier Inc.
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HKI-272 and Rapamycin Inhibit Murine Lung Canceron long exposure of the phospho-EGFR (Tyr1068) blot
(Figure 6C). HKI-272 treatment did not lead to complete
inactivation of secondary signaling molecules, including
Akt and Erk, as evidenced by the residual phosphorylation
persisting on Akt (Ser473) and Erk (Thr202/Tyr204), demon-
strated on long exposure of the respective blots. Similarly,
mTOR signaling was incompletely abrogated by HKI-272
treatment, as p70S6K (Thr389) and S6 (Ser240/244) re-
mained phosphorylated (Table S1). In contrast to the
complete dephosphorylation of S6 in H3255 cells by
HKI-272 treatment, the reduction in S6 phosphorylation
at Ser240/244 in H1975 cells was modest and reversed
within 24 hr. As in H3255 cells, rapamycin treatment of
H1975 cells resulted in reduced phosphorylation of S6
by 12 hr, with increased Akt phosphorylation over time.
Most importantly, HKI-272 and rapamycin combination
treatment of H1975 cells inhibited not only EGFR phos-
phorylation but also downstream PI3K-Akt and mTOR
signaling. Identical results were obtained using H820
(E746_T751del-T790M) cells treated with HKI-272, rapa-
mycin, or the HKI-272-rapamycin combination (data not
shown). These data are consistent with the synergy of
HKI-272 and rapamycin in cell lines with the T790M sec-
ondary mutation and support the superior treatment
effects of combination therapy observed in the EGFR TL
animal model.
To confirm the in vitro data, mice bearing EGFR TL-
driven tumors were treated with HKI-272, rapamycin,
and the combination of both drugs for 48 hr, followed by
immunohistochemical staining of signaling molecules
including phospho-EGFR, phospho-ErbB2, phospho-
ErbB3, phospho-Akt, phospho-MAPK, and phospho-S6.
HKI-272 alone effectively decreased the expression level
of phospho-EGFR and ErbB2, but not ErbB3 in peripheral
tumors. While downstream signaling of ErbB family mem-
bers such as Akt and MAPK were also inhibited, expres-
sion of phospho-S6 was not altered dramatically with
HKI-272 monotherapy. Rapamycin alone significantly de-
creased phospho-S6 staining in peripheral tumors, while
phospho-EGFR, ErbB2, ErbB3, Akt, and phospho-MAPK
remained intact. In contrast, the combination of the two
drugs strongly inhibited phospho-EGFR, ErbB2, and
phospho-S6 staining as well as phospho-Akt and MAPK
in peripheral tumors and induced a dramatic increase in
caspase 3 staining (Figure 7 and Figure S3). Bronchial tu-
mors demonstrated a response pattern similar to that ob-
served in peripheral tumors, although to a lesser degree
(data not shown), potentially due to higher baseline levels
of expression of EGFR, ErbB2, and ErbB3 (Figure S1), as
well as Akt and S6 (data not shown). In summary, these
data demonstrate that HKI-272 and rapamycin combina-
tion therapy inhibits both upstream and downstream sig-
naling of the EGFR/PI3K/mTOR axis both in vitro and
in vivo, accounting for the cytotoxic synergy of these drugs.
DISCUSSION
In the current study, we demonstrate that EGFR harboring
the compound kinase domain L858R and T790M mutationis oncogenic in vivo. As expected, these tumors are resis-
tant to erlotinib despite retaining full addiction to EGFR
signaling for survival, thereby validating that the mutant
EGFR remains a promising therapeutic target, even in
the setting of erlotinib resistance.
We were initially surprised that EGFR TL-driven tumors
demonstrated a suboptimal response to the irreversible
TKI HKI-272. HKI-272 was initially reported to be sufficient
to inhibit growth of the H1975 lung cancer cell line with the
EGFR TL mutation (Kwak et al., 2005) that is resistant to
erlotinib. However, our data indicate that the efficacy of
the drug appears to be greater against cells expressing
EGFR harboring the L858R point mutation alone. These
results are also supported by the relative potency of
HKI-272 in a Ba/F3 system with artificial expression of ei-
ther EGFR TL or EGFR L858R (Ji et al., 2006b). Consistent
with these in vitro data, HKI-272 demonstrated excellent
activity against lung adenocarcinomas driven by EGFR
L858R (Ji et al., 2006a), but limited efficacy against periph-
eral tumors driven by EGFR TL, and no efficacy against
EGFR TL-driven bronchial tumors. Importantly, this result
is concordant with emerging preliminary data from a multi-
site phase I clinical trial of HKI-272. In this initial experi-
ence, although 5 of 12 previously treated NSCLC patients
achieved stable disease of varying duration up to 24
weeks, no confirmed partial responses were observed
(K.K. Wong et al., 2006, J. Clin. Oncol., abstract). Thus,
the therapeutic studies in our mouse model may be reflec-
tive of the clinical activity observed in ongoing human lung
cancer HKI-272 trials.
The PI3K-mTOR axis is a pivotal pathway downstream
of EGFR that governs the sensitivity of NSCLC cells to
EGFR TKIs (Engelman and Cantley, 2006; Engelman
et al., 2005). This view is supported by the finding that er-
lotinib synergizes with rapamycin in a subset of NSCLC
harboring wild-type EGFR (Buck et al., 2006). Experiments
in EGFR TL-driven cell lines revealed that rapamycin syn-
ergizes with HKI-272 to inhibit survival. Unlike HKI-272
alone, the combination abrogates the PI3K/Akt and
mTOR pathway more effectively. These results are also
reflected in vivo, where HKI-272 and rapamycin combina-
tion therapy induces much more dramatic tumor regres-
sion than HKI-272 monotherapy in our EGFR TL-driven
mouse model. Taken together, the data suggest that the
treatment strategy of irreversible EGFR inhibition and
mTOR inhibition may induce a more promising response
rate against NSCLC with acquired erlotinib resistance.
Our work points to a potential limitation of irreversible
inhibitors against EGFR harboring a T790M secondary ki-
nase domain mutation, since mTOR signaling may not be
completely suppressed. The results in H1975 cells sug-
gest that even minimal EGFR activity may be sufficient
to maintain significant mTOR activity, so that the potency
of EGFR TL inhibition by an irreversible inhibitor is a critical
issue. Our data do not rule out the possibility that other
irreversible EGFR/ErbB2 inhibitors will have improved
potency to cause more complete suppression of the
EGFR-Akt-mTOR-S6 axis and therefore will not require
rapamycin-mediated synergism to achieve response inCancer Cell 12, 81–93, July 2007 ª2007 Elsevier Inc. 89
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ment Reveals that Phosphorylation of
EGFR Family Members and Downstream
Signaling Molecules Respond Differently
to HKI-272, Rapamycin, or the Combina-
tion of Both Drugs
EGFR TL mice were treated with HKI-272,
rapamycin, or the combination therapy for
48 hr, and lung sections were then stained with
antibodies recognizing phospho-EGFR, phos-
pho-ErbB2, phospho-ErbB3, phospho-Akt,
phospho-MAPK, and phospho-S6. Photos
shown are representative fields from duplicate
animals in each group. IHC photographs show
low-magnification (1003) pictures (insets) and
high-magnification (8003) pictures.tumors harboring a T790M mutation. Lastly, our data do
not exclude the possibility that, in lung cancer cells har-
boring EGFR TL, engagement of alternative signaling
pathways downstream of other receptor tyrosine kinases
may independently activate the mTOR axis when EGFR
is inhibited.
Despite the importance of mTOR signaling, lung adeno-
carcinomas driven by EGFR TL are relatively insensitive to
growth inhibition by rapamycin alone. Although phospho-
S6 may be important for the tumor maintenance in these
EGFR TL-driven lung cancers, its inhibition is not sufficient
to halt tumor growth. In addition, we observed enhanced
phosphorylation of Akt in response to rapamycin. This
increase in Akt phosphorylation is consistent with the find-
ing that the rapamycin analog RAD001 results in increased
Akt phosphorylation in human lung tumors (O’Reilly et al.,
2006). However, because PI3K is primarily driven by
EGFR-mediated phosphorylation of ErbB3 in these can-
cers (Engelman et al., 2005), rapamycin is unlikely to
have the untoward side effect of increasing Akt signaling
when combined with HKI-272 in this setting (consistent
with the observations in Figure 6). We have also confirmed
that erlotinib was unable to synergize with rapamycin to
compromise the survival of the NSCLC harboring EGFR
T790M secondary mutation, again indicating the need to
effectively inhibit EGFR and other upstream signaling
events.90 Cancer Cell 12, 81–93, July 2007 ª2007 Elsevier Inc.Although HKI-272 alone had limited efficacy against pe-
ripheral tumors, bronchial tumors were completely resis-
tant. The mechanistic basis for the relative resistance of
the bronchial tumors to HKI-272 remains unclear, but it
is possible that there may be differences in the ratio and
composition of EGFR homodimers and heterodimers in
bronchial and alveolar epithelial cells. Interestingly, HKI-
272 is expected to bind to an inactive conformation of
the EGFR, in which the so-called C helix is displaced
from the active site. Activating dimerization interactions
have been shown to push the C helix into its active confor-
mation (Zhang et al., 2006) and would therefore be
expected to prevent efficient binding of HKI-272. Thus,
potential differences in ligand expression in these two
tumor environments could explain the relative lack of sen-
sitivity to HKI-272 in the bronchial tumors. We have indeed
observed that the intensity of phospho-EGFR, ErbB2, and
ErbB3 staining is higher in bronchial than peripheral
tumors (Figure S1), supporting this hypothesis.
The EGFR TL double mutation may also alter the extent
of heterodimerization with ErbB3, or the efficiency of
phosphorylation of the ErbB3 sites that recruit and acti-
vate PI3K, which could lead to tumors in bronchial epithe-
lium where this ErbB family member or its ligand are more
highly expressed. Of note, normal bronchial epithelium is
positive for phosphorylated EGFR and ErbB2 staining,
while positive IHC staining of these proteins is almost
Cancer Cell
HKI-272 and Rapamycin Inhibit Murine Lung Cancerabsent in alveolar epithelium (Figure 3A and Figure S1).
Additionally, we have observed that activated mutant
ErbB2 induces tumors in the lung bronchial epithelium
(unpublished data). Therefore, the existence of EGFR
TL-driven tumors in ErbB2-expressing bronchial epithelia
suggests that EGFR /ErbB2 heterodimers may play an im-
portant role in both EGFR- and ErbB2-initiated mouse
lung cancers, thereby supporting the hypothesis that
ErbB2 and EGFR signaling work synergistically in at least
a subset of EGFR-driven lung tumors (Cappuzzo et al.,
2005). Since bronchial tumors are absent in the either
EGFR L858R- or EGFR T790M-driven mouse lung cancer
model (Ji et al., 2006a and unpublished data), it is possible
that an unique EGFR/ErbB2 interaction only exists be-
tween ErbB2 and EGFR TL but not the EGFR single point
mutation (L858R or T790M). It is also possible that, in the
EGFR TL mice, the expression levels of ErbB2 and ErbB3
might be different in the alveolar and bronchial compart-
ments and thus contribute to the observed phenotype.
Although an EGFR/ErbB2 dual inhibitor like HKI-272
should theoretically inhibit function of both EGFR/ErbB3
and ErbB2/ErbB3 heterodimers, our IHC data show that
HKI-272 did not completely block phospho-ErbB2 and
EGFR signaling, even when the HKI-272 dose was in-
creased to 150 mg/kg/day (data not shown). Achievable
concentrations of the drug in different types of tumors
may also be different due to different diffusion barriers in
bronchial and peripheral tumors. Recently, Sergina et al.
showed that residual ErbB2 kinase activity can drive re-
fractory ErbB3 phosphorylation in multiple cell lines and
xenograft animal models (Sergina et al., 2007), which
may partially explain our observations in the de novo
transgenic lung cancer model.
Bronchiolar Clara cells and alveolar type II pneumocytes
arise from the same precursor cells (Kim et al., 2005). Ex-
istence of both bronchial and peripheral tumors in our
EGFR TL-driven lung cancer mouse model, as well as
distinct SPC and CCSP staining patterns of these two
types of tumors, suggest that the oncogene was actually
expressed in the precursor cells that possess the potential
to differentiate into both Clara cells and type II pneumo-
cytes. However, it remains unclear why the EGFR TL dou-
ble mutation gives rise to bronchial tumors, while the
L858R single mutation does not. It is likely that the double
mutation ‘‘hyperactivates’’ the kinase. The equivalent of
the T790M residue is well known from the earliest studies
of other oncogenic tyrosine kinases and has been termed
the ‘‘gatekeeper’’ residue because the presence of large
versus small amino acids in this position controls access
to a pocket that can be exploited in inhibitor design. The
corresponding mutation introduced into c-Src confers
a transforming phenotype (Kato et al., 1986). The equiva-
lent mutation also arises in Bcr-Abl (T315I) in imatinib-
treated CML patients, where it confers inhibitor resistance,
and has also been shown to pre-exist in nontreated popu-
lations (Bell et al., 2005). These findings indicate that the
mutation may be an activating mutation in these kinases,
or may otherwise confer a selective advantage even in
the absence of inhibitor. Thus, the T790M mutation maylead to a higher degree of catalytic activation of the
EGFR, particularly in concert with other activating
mutations, such as L858R. This hypothesis is particularly
attractive given the discovery that a single EGFR TL allele
confers gefitinib resistance in a lung cancer cell line with
more than 40 amplified EGFR alleles (Engelman et al.,
2006).
In summary, we have generated a mouse model of lung
adenocarcinoma driven by EGFR TL that mimics human
lung cancers with acquired resistance to erlotinib. We ob-
served that combination therapy involving the irreversible
EGFR/ErbB2 TKI HKI-272 and the mTOR inhibitor rapa-
mycin led to dramatic tumor regression. Our study sug-
gests that an irreversible TKI combined with rapamycin
or other rapamycin analogs such as CCI-779 or RA0001
may be of benefit to NSCLC patients with T790M-medi-
ated acquired erlotinib resistance. This animal model
may be of value in screening newer-generation EGFR
inhibitors as well as other therapeutic agents and drug
combinations prior to human clinical trials and provides
a platform to study crosstalk between different oncogenic
or tumor suppressor signaling pathways and aberrant
EGFR signaling.
EXPERIMENTAL PROCEDURES
Generation of the CCSP-rtTA/Tet-op-EGFR TL Mouse Cohort
To generate the Tet-op-EGFR TL transgenic mice, site-directed
mutagenesis was performed on the pCIBA-hEGFR plasmid (provided
by Dr. Nabeel Bardeesy). The fragment containing the whole hEGFR
ORF with the Kozak site was then subcoloned into pTRE2-hyg (Clon-
tech, Mountain View, CA). The constructs were then digested to
release the entire allele containing Tet-op-EGFR TL-b-globin polyA.
Transgenic mice were then generated by injection of the construct
into FVB/N blastocysts. Progeny were genotyped and characterized
as described in the Supplemental Data. All mice were housed in a path-
ogen-free environment at the Harvard School of Public Health and
were handled in strict accordance with Good Animal Practice as
defined by the Office of Laboratory Animal Welfare, and all animal
work was done with Dana-Farber Cancer Institute IACUC approval.
RT-PCR and Quantitative PCR
Total RNA samples were prepared as previously described (Ji et al.,
2006a) and then retrotranscribed into first-strand cDNA using the
Superscript First Strand Synthesis System following the manufac-
turer’s protocol (Invitrogen, Carlsbad, CA). Quantitative PCR was per-
formed by monitoring the increase in fluorescence of SYBR green dye
in real-time (Qiagen, Valencia, CA) with an ABI 7700 sequence detec-
tion system (PerkinElmer Life Sciences, Waltham, MA). Primers used
for RT-PCR and real-time PCR are listed in the Supplemental Data.
Immunohistochemistry and TUNEL Assays
Mice were sacrificed and left lungs were snap frozen; right lungs were
fixed in 10% formalin, embedded in paraffin, and sectioned at 5 mm, as
described previously (Ji et al., 2006a). Histological analyses were
performed as described in the Supplemental Data.
Targeted Therapy Using the EGFR Inhibitors HKI272,
Erlotinib, and/or Rapamycin
After continuously exposure to doxycycline diets for more than
8 weeks, bitransgenic mice were subjected to MRI to document
the lung tumor burden. After initial imaging, either HKI-272 (Wyeth
Pharmaceuticals, Pearl River, NY) or erlotinib (Biaffin GmbH & Co
KG, Kassel, Germany) formulated in 0.5% methocellulose-0.4%Cancer Cell 12, 81–93, July 2007 ª2007 Elsevier Inc. 91
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HKI-272 and Rapamycin Inhibit Murine Lung Cancerpolysorbate-80 (Tween 80) were administrated by gavage at 50 mg/kg
daily. Rapamycin (LC laboratories, Woburn, MA) formulated in 5%
PEG400 and 5% Tween 80 was administrated by i.p. injection at
2 mg/kg daily. The same mice were imaged by MRI to determine the
reduction in tumor volume weekly during the respective treatments
and then sacrificed for further histological and biochemical studies.
HKI-272 treatment was continued for 3 weeks to induce maximal tu-
mor response. Erlotinib treatment was stopped after 2 weeks due to
increasing tumor burden. Littermates were used as control for all treat-
ment groups.
Tumor Cell Lines and Drug Treatment
NCI-H1975, NCI-H3255, and NCI-H820 NSCLC cell lines (designated
H1975, H3255, and H820, respectively) were obtained from the Amer-
ican Type Culture Collection (Rockville, MD), and HCC827 cells were
generously provided by Dr. Adi Gazdar. All cell lines were maintained
in the recommended growth medium.
Both HKI-272 and rapamycin were reconstituted in DMSO (10 mM
and 100 mM as stock solution) and used at the indicated concentra-
tions.
Cell Proliferation Assays and Western Blot Analysis
MTT assay and western blotting were done as described in the Sup-
plemental Data (Shimamura et al., 2005). Combination indices (CI)
were calculated by the Median Effect Method, available on Calcusyn
(Biosoft, Cambridge, UK).
MRI Scanning and Tumor Volume Measurement
MRI scanning and tumor volume measurement were described
elsewhere and in the Supplemental Data (Li et al., 2007).
Statistics
Statistical analyses were performed using unpaired two-tailed
Student’s t test. p values of less than 0.05 were considered significant.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, three supplemental figures, and one supplemental table and
can be found with this article online at http://www.cancercell.org/
cgi/content/full/12/1/81/DC1/.
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